This CME program will outline current and emerging antisense therapeutics for the treatment of patients with spinal muscular atrophy (SMA). Dr. Basil Darras and Dr. John Brandsema will discuss the importance of early diagnosis and presymtomatic treatment in SMA. Current clinical trial data of available therapies for SMA will be analyzed. The expert faculty will relay best practices for utilizing the interprofessional team and shared decision making for patients with spinal muscular atrophy. At the conclusion of this educational activity, learners will be better acquainted with optimal treatment and management techniques for patients with SMA.
Neurologists, pediatricians, primary care physicians, nurse practitioners, nurses, and other healthcare professionals who care for patients with spinal muscular atrophy
- Review screening techniques and stress the importance of early diagnosis and presymptomatic treatment initiation in infant and pediatric populations with spinal muscular atrophy.
- Analyze all recent clinical trial data for spinal muscular atrophy therapeutics to inform clinical decision making.
- Implement an interprofessional team approach in order to improve outcomes for patients with spinal muscular atrophy.
Basil Darras, MD
Chief-Division of Clinical Neurology
Director, Neuromuscular Center and Spinal Muscular Atrophy Program
Boston Children’s Hospital
Professor of Neurology, Harvard Medical School
John Brandsema, MD
Neuromuscular/General Neurology & Electromyography
Neuromuscular Education Director and Neuromuscular Section Head
Children’s Hospital of Philadelphia
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Faculty||Relationship Identified With:|
|Basil Darras, MD||Consultant/Advisor: AveXis, Inc.; Biogen; Bristol-Myers Squibb Company; Cytokinetics, Inc.; F. Hoffman-La Roche Ltd; Marathon Pharmaceuticals; PTC Therapeutics; Santhera Pharmaceuticals; Sarepta TherapeuticsGrant/Research Support: Biogen; CureSMA; Cytokinetics, Inc.; F. Hoffman-La Roche Ltd; Ionis Pharmaceuticals; National Institute of Health/National Institute of Neurological Disorders and Stroke; PTC Therapeutics; Santhera Pharmaceuticals; Sarepta Therapeutics; Slaney Family Fund for SMA; SMA Foundation; Summit Pharmaceuticals International Corporation; Working on Walking FundSpeaker’s Bureau: Biogen|
|John Brandsema, MD||Consultant/Advisor: AveXis, Inc.; Biogen; Cytokinetics, Inc.Speaker’s Bureau: Biogen|
Planners, Managers, Reviewers
Timothy Hayes, MD, PhD; Nicole Brestowski and Chelsey Benedek hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AcademicCME designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been supported by an independent educational grant from Biogen.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Biogen do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions.
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Healthcare providers who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME Certificate.
- All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
CE Inquiries/Special Needs
For all CE inquiries or special needs, please contact [email protected].